Founded with technology from Drs. John He and Kyung Lee at Icahn School of Medicine at Mount Sinai, Rila is developing novel programs to create safe and effective anti-fibrotic treatments. Our lead program is a first-in-class small molecule allosteric inhibitor targeting HIPK2 in kidney fibrosis and will be entering IND-enabling studies in October 2022.There is a large unmet need to address renal fibrosis, which underlies the progression of chronic kidney disease to end-stage renal failure.
Rila Therapeutics Exits Stealth Mode

Leadership Team

John Cijiang
John Cijiang He, MD, PhD
Michael Hui
Michael Hui
Founder and Chairman
Kyung Lee
Kyung Lee, PhD
Robert Drakas
Robert Drakas, PhD
Interim CEO
Shang Pharma Innovation
Shang Pharma Innovation identifies transformational healthcare discoveries at leading research labs and medical centers, then provides the right combination of resources needed to reach critical development milestones.
Interested in partnering with Rila? CONTACT